H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result

With strong 1-year returns and upside potential, DBV Technologies S.A. (NASDAQ:DBVT) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026.

On December 17, 2025, H.C. Wainwright raised its price target on DBV Technologies S.A. (NASDAQ:DBVT) from $35 to $40, while reiterating a “Buy” rating, The Fly reported. The firm described the Phase 3 VITESSE trial as a clear execution milestone that materially de-risks the VIASKIN Peanut program. With the company reporting strong results in 4-7-year-old peanut-allergic children, the analyst’s confidence in a straightforward regulatory path is reinforced, supporting a Biologics License Application (BLA) submission in the first half of 2026.

The previous day, DBV Technologies S.A. (NASDAQ:DBVT) announced that its pivotal VITESSE study met its primary endpoint. After 12 months of VIASKIN Peanut patch treatment, 46.6% of children achieved clinically meaningful desensitization, compared with 14.8% on placebo. This is a statistically significant outcome that exceeded prespecified thresholds. Furthermore, the trial showed a favorable safety profile, high compliance, and low discontinuation rates. With these positive trial results, the company reinforced the patch’s potential as a non-invasive treatment option.

The positive trial results also drew the attention of the investment banking firm Citizens, which raised its price target from $21 to $45 on December 17, 2025, while maintaining an “Outperform” rating, according to The Fly. Beyond clinical efficacy, the bank expects VITESSE’s success to accelerate warrant exercises and potentially unlock $181 million in cash. According to DBV Technologies S.A. (NASDAQ:DBVT), this could be sufficient to support a potential U.S. launch in the 4-7-year-old population.

These analyst views reflect how clinical success and financial flexibility are converging for DBV as it advances toward regulatory submission.

DBV Technologies S.A. (NASDAQ:DBVT) focuses on developing non-invasive immunotherapies, led by its VIASKIN patch technology. The patch aims at desensitizing patients with food allergies and addresses significant unmet needs in pediatric care.

While we acknowledge the potential of DBVT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Cheap Gold Stocks to Buy Now and READ NEXT: 15 Best AI Stocks to Watch in December 2025..

Disclosure: None.